

Navigation et recherche sur le web des études de ClinTrial Refer IFM

L'application ClinTrial Refer, disponible sur smartphone, est également disponible en version Web

<https://web.clintrialreferapp.com/SearchTrial/List>

à filtrer selon vos recherches

ClinTrial Refer | 2020

Id	Scientific Title	Registration	Acronym	Status	Actions
20050168	A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma	NCT04318080	Tislelizumab in Part...	Pending	Details
20050167	Randomised Evaluation of Sodium Dialysate Levels on Vascular Events	NCT02822821	RESOLVE	Open	Details
20050166	Canadian-Australian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease	NCT03674307	Screening for Asympt...	Open	Details
20050165	To determine whether medical management including maintenance dialysis versus medical treatment alone reduces mortality and morbidity in highly co-morbid patients aged over 75 years with stage 5 chronic kidney disease,	ACTRN12617001532392	DISCERN	Open	Details
20050164	REDUcing the burden of dialysis Catheter ComplicaTIOns in patients with kidney disease: a National approach	ACTRN12616000830493	REDUCCION	Open	Details
20050163	Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease	NCT03669953	Treatment of Cardio...	Pending	Details
20050162	An Investigator-Initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.	NCT03373089	PHOSPHATE	Open	Details
20050161	An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of ICN5-FB-UP, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy	NCT04014335	ICN5	Open	Details
20050160	Glomerular Disease Registry	ACTRN12619001429145	GRIT	Open	Details

Par promoteur

ClinTrial Refer | 2020

Intergroupe Francophone Du Myelome

We have found 2 trials matching your criteria

Id	Scientific Title	Registration	Acronym	Status	Actions
20020407	Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Desamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Prognostic	NCT03968377	IFM 2014-01	On Hold	Details
20020405	Evaluation of the Impact of the Update Multiple Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Prognostic: Evaluation of Smoldering Myeloma (CARRISMM)	NCT04144387	CARRISMM IFM 2017-06	On Hold	Details

Showing 1 to 2 of 2 entries

Previous 1 Next

Show 25 entries

Par ex pour le myélome , centres ouverts en France :

Refine By ✕ Clear All

Discipline ✕ Clear ✕ Haematology ✕ Multiple Myeloma (MM) ✕ France

Health Conditions ✕ Clear

Category

Sub Category

Primary Sponsor

Country ✕ Clear

france

France (8)

Region

We have found 8 trials matching your criteria

Id	Scientific Title
20040307	A Phase 2 Study of Daratumumab Subcutaneous (Dara- With Daratumumab Intravenous (Dara-IV) to Evaluate D
20040306	An Open-label, Multicenter, Dose Escalation Phase 1b S Refractory Multiple Myeloma
20020410	A Multi-center Phase III Randomized Study Comparing C

Puis cliquer sur détails de l'étude choisie

Partages avec moi - OneDrive | Courrier - marie-odile PET | ClinTrials Refer | ClinTrials Refer

https://web.clintrialsreferapp.com/SearchTrial/List

ClinTrials Refer

Refine By ✕ Clear All

Discipline ✕ Clear ✕ Haematology ✕ Multiple Myeloma (MM) ✕ France

Health Conditions ✕ Clear

Category

Sub Category

Primary Sponsor

Country ✕ Clear

france

France (8)

Region

Location

Status

Advanced

We have found 8 trials matching your criteria

Id	Scientific Title	Registration	Acronym	Status	Actions
20040307	A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Decamethasone (DKS) Compared With Carfilzomib and Decamethasone (iG) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment	NCT03871829	54767414MMY2005 LY...	Open	Details
20040306	An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma	NCT02519452	54767414MMY1004 PA...	Open	Details
20020410	A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Decamethasone for Relapsed Multiple Myeloma	NCT03898014	CDMPR04 IFM 2018-07	Open	Details
20020409	An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a Phase II Study of the Intergrupe Francophone du Myelome "IFM 2018-04"	NCT03605077	IFM 2018-04	Open	Details
20020408	A Multicentre Open-label Phase II Study of Ixazomib-Daratumumab Without Decamethasone (Dara) in Elderly Relapsed Refractory Multiple Myeloma	NCT03767221	IFM 2018-02	On Hold	Details
20020407	Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Decamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Prognostic	NCT03683277	IFM 2014-01	On Hold	Details
20020406	A Phase III Study Comparing Lenalidomide and Subcutaneous Daratumumab (R-Dara SC) vs Lenalidomide and Decamethasone (Rd) in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy	NCT03939312	IFM 2017-03	On Hold	Details
20020405	Evaluation of the Impact of the Update Multiple Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Prognostic Evaluation of Smoldering Myeloma (CARRISM)	NCT01440887	CARRISM IFM 2017-04	On Hold	Details

Showing 1 to 8 of 8 entries

Previous 1 Next

ClinTrials Refer | 2020

Tapez ici pour rechercher

17:00

Pour accéder à la fiche détaillée,

← → ↻ 🏠 <https://web.clintrialreferapp.com/SearchTrial/Details?trialId=XnYNwgdTKOg%3D> 📖 ☆ ⚙️ 📄 📄 ⋮

ClinTrial Refer

🏠 Back to List/Filter

Trial Acronym
IFM 2014-01

Registration Number
NCT03683277

Scientific Title
Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic

Brief Summary | Key Inclusion Criteria | Key Exclusion Criteria | Trial Locations | Primary Sponsor

This study is a Multicenter, Open-label, Phase II study of Ixazomib, plus Pomalidomide and Dexamethasone regimen (IPO) in RRMM with adverse Genomic Abnormalities.

Website URL
Link Name | Link URL
Clinicaltrials.gov | <https://clinicaltrials.gov/ct2/show/NCT03683277>

Secondary IDs N/A	Study Type Interventional	Intervention Code Treatment - Drugs	Phase Phase 2
Minimum Age 18	Maximum Age 120	Date Registered 11/02/2020	Date Closed N/A
Status On Hold	Enrolment Type By Specialist and/or Surgeon Referral		

Mutation Status and Biomarker
[Any or no status?](#)

Is it a Cohort Trial? No	Is this a Tele-Trial? No	Can healthy volunteer participate? No
------------------------------------	------------------------------------	-------------------------------------------------

Discipline
Haematology

Health Condition
Multiple Myeloma (MM)

Category
N/A

Sub Category
N/A

<https://web.clintrialreferapp.com/SearchTrial/Details?trialId=XnYNwgdTKOg%3D#P5>

16:56

Et ouvrir les onglets selon les besoins ,

Myeloma (CARRISMM)

Brief Summary | **Key Inclusion Criteria** | **Key Exclusion Criteria** | **Trial Locations** | **Primary Sponsor**

Trial Location Name

Address

Les centres ouverts , leur statut et les contacts sont sous 'Trial locations'

Partagés avec moi - t | Courrier - marie-odil | CSONline | ClinTrial Refer | ClinTrial Refer | ClinTrial Refer

← → ↻ 🏠 <https://web.clintrialreferapp.com/SearchTrial/Details?trialId=QC3dltUBans%3D> 📖 ☆ ⚙️ 📄 📄 ⋮

ClinTrial Refer

🏠 Back to List/Filter

Trial Acronym
CARRISMM IFM 2017-04

Registration Number
NCT04144387

Scientific Title
Evaluation of the Impact of the Update Multiple Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Prognostic Evaluation of Smoldering Myeloma (CARRISMM)

Brief Summary | Key Inclusion Criteria | Key Exclusion Criteria | **Trial Locations** | Primary Sponsor

Trial Location Name	Address	Status
APHP Bobigny-Avicennes	125 Rue de Stalingrad, Bobigny, France	On Hold
Primary Contact : Vincent Levy (LYSA), vincent.levy@avc.aphp.fr , +33 1 48 95 55 55		
Secondary Contact : Sabine Brechignac (IFM) , sabine.brechignac@aphp.fr , +33 0148955352		
APHP Cochin	27 Rue du Faubourg Saint-Jacques, Paris, France	On Hold
Primary Contact : Benedicte Deau-Fischer (LYSA), benedicte.deau-fischer@aphp.fr , +33 1 58 41 41 41		
Secondary Contact : Didier Bouscary (IFM) , didier.bouscary@aphp.fr , +33 1 58 41 21 31		
APHP Henri Mondor	51 Avenue du Maréchal de Lattre de Tassigny, Créteil, France	On Hold
Primary Contact : Corinne Haioun (LYSA), corinne.haioun@aphp.fr , +33 1 49 81 21 11		
Secondary Contact : Kevin Dalbec (IFM) , kevin.dalbec@aphp.fr , +33 1 49 81 21 11		

Taper ici pour rechercher

17:17
11/05/2020